Molly Henderson Sells 3,678 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 3,678 shares of the stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $4.55, for a total transaction of $16,734.90. Following the transaction, the chief financial officer now owns 89,868 shares in the company, valued at approximately $408,899.40. This represents a 3.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Molly Henderson also recently made the following trade(s):

• On Tuesday, January 21st, Molly Henderson sold 6,583 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $6.59, for a total value of $43,381.97.

Phathom Pharmaceuticals Price Performance

Phathom Pharmaceuticals stock traded down $0.62 during mid-day trading on Tuesday, reaching $4.25. 937,718 shares of the company traded hands, compared to its average volume of 1,005,362. The firm’s fifty day moving average is $5.66 and its two-hundred day moving average is $9.51. The company has a market capitalization of $295.96 million, a price-to-earnings ratio of -0.75 and a beta of 0.35. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $4.07 and a fifty-two week high of $19.71.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Wasatch Advisors LP raised its position in Phathom Pharmaceuticals by 531.3% during the 4th quarter. Wasatch Advisors LP now owns 1,558,928 shares of the company’s stock worth $12,658,000 after buying an additional 1,311,986 shares during the last quarter. FMR LLC grew its position in shares of Phathom Pharmaceuticals by 49,000.7% during the 3rd quarter. FMR LLC now owns 1,304,114 shares of the company’s stock valued at $23,578,000 after acquiring an additional 1,301,458 shares during the period. Jennison Associates LLC increased its position in shares of Phathom Pharmaceuticals by 20.4% in the fourth quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock valued at $57,348,000 after buying an additional 1,196,118 shares in the last quarter. Tang Capital Management LLC acquired a new position in Phathom Pharmaceuticals during the fourth quarter worth $4,060,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Phathom Pharmaceuticals during the 4th quarter worth about $3,701,000. 99.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PHAT has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Wednesday, April 2nd. Cantor Fitzgerald raised shares of Phathom Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th. The Goldman Sachs Group lowered their price target on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a “neutral” rating on the stock in a report on Monday, March 10th. HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Phathom Pharmaceuticals in a report on Wednesday, April 2nd. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $22.17.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.